Skip to main content

Table 3 Trials designed to compare the new oral anticoagulants to prevent thromboembolism with warfarin in AF

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Trial Study drug Dosing Number of patients Design
RE-LY Dabigatran 110 mg twice daily, 150 mg twice daily 18,113 Randomized, open-label, noninferiority
Rocket-AF Rivaroxaban 15 mg daily, 20 mg daily 14,000 Randomized, double blind, noninferiority
ARISTOTLE Apixaban 5 mg twice daily 15,000 Randomized, double blind, noninferiority
Engage AF Edoxaban 30 mg daily, 60 mg daily 16,500 Randomized, double blind, noninferiority